Coherus BioSciences has filed terms for its upcoming IPO, estimating shares to be priced between $12 and $15 each. If priced at its range midpoint, it would command a market cap of $432.7 million. Developing treatments for inflammatory diseases, the company has raised about $118 million in VC, with its last financing in May raised at a valuation of $265 million. Lilly Ventures holds an 11.17% pre-IPO stake, with Sofinnova Venture Partners and Venrock holding 8.28% and 7.65% stakes, respectively. Coherus will list on the NASDAQ under the symbol CHRS.